Prof. Jean-Yves Reginster

Google scholar: https://scholar.google.com/citations?user=hLj70l8AAAAJ

C.V summery: http://www.ema.europa.eu/docs/en_GB/document_library/contacts/jreginster_CV.pdf

Joint Research with the chair:

• Pitfalls in the measurement of muscle mass: a need for a reference standard.
• Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
• Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
• Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.
• Does nutrition play a role in the prevention and management of sarcopenia?
• Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting.
• Quality of life assessment in musculo-skeletal health.
• Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting.
• Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.
• Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.
• Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO).
• Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
• Sarcopenia in daily practice: assessment and management.